Jackson Acquisition Company II logo

Jackson Acquisition Company II(JACS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 301 days
PROFIT SINCE LAST BUY
+4.93% ▲
LAST CLOSE
$10.86
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for JACS

11/13/2026: JACS (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Jackson Acquisition Company II is a blank check company formed to pursue a business combination within the healthcare services and technology sectors. The company's main strength is its experienced management team and substantial capital trust established during its IPO. Its primary investment story centers on the potential to identify and take a high-growth private healthcare enterprise public. Key risks include the pre-revenue operating status, intense deal competition, and strict timeline pressures to execute a merger. The stock suits event-driven investors seeking exposure to healthcare M&A catalysts while monitoring progress toward an initial business combination.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe company currently lacks active commercial operations or revenue-generating products.
Momentum investorStrong fit while signal remains positiveEvent-driven trading can create short-term momentum around potential deal announcements.
Value investorMixed fitValuation is primarily tied to the cash value held in trust rather than underlying business earnings.
Dividend investorWeak fitThe company does not pay dividends, offering no regular income stream.
Low-risk investorMixed fitWhile trust assets provide downside protection near redemption value, execution and timing risks remain.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMediumShare prices can fluctuate based on deal rumors, market sentiment, and proximity to combination deadlines.
Valuation riskMedium / highThe ultimate valuation of the target business acquired may not sustain post-merger trading value.
Competition risk (healthcare SPAC deal flow)HighIntense competition from other financial buyers for attractive healthcare targets can impede deal completion.
Business qualityHighAs a shell entity, business quality depends entirely on the yet-to-be-identified target company.
Dividend incomeLow / noneNo dividend distributions are paid to common shareholders.
Execution riskHighFailure to complete a business combination within the required window will trigger liquidation.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 321.35M USD
Price to earnings Ratio 38.79
1Y Target Price -
Price to earnings Ratio 38.79
1Y Target Price -
Volume (30-day avg) 64.9K shares
Beta -
52 Weeks Range 10.41 - 10.92
Updated Date 11/15/2026
52 Weeks Range 10.41 - 10.92
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.28

Sector & Industry Intelligence

Sector

Financial Services

Constructive
Sentiment
Bullish
Momentum
BUY Breadth Improving
BUY participation
50.4%
Active BUY / eligible
61 / 121
30-Day BUY Count Change
+45
Market state
Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Shell Companies

BUY participation
100.0%
Active BUY / eligible
1 / 1
30-Day BUY Count Change
+1

Eligible universe: 1 stock.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Flat / Range-Bound
PRICE PATH

Flat / Range-Bound

The stock price has been trading within a narrow range with minimal directional movement.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type Stock
Historic Profit 4.93%
Avg. Invested days 301
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 5.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
JACS receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
JACS has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+2292.0%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
JACS's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is JACS's strongest growth driver at +2292.0% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (+0.0%, slightly negative) and free-cash-flow growth (-41.2%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 102.0% and approximately 67.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.06%, which materially reduces the ownership score.

Top 5 Institutional Investors

Mizuho Securities USA Inc 5.48%
Hudson Bay Capital Management LP 5.14%
Glazer Capital, LLC 4.04%
Westchester Capital Management LLC 4.01%
Cnh Partners, LLC 3.95%

Unit Economics (Per $1K Revenue)

★★★★★
JACS generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
JACS has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Trust Interest IncomeInterest earned on cash and U.S. government treasury securities held inside the trust account.The company does not sell products or services; its minimal income comes entirely from interest on cash held in trust.

Valuation

Trailing PE 38.79
Forward PE -
Enterprise Value 321.25M
Price to Sales(TTM) -
Enterprise Value 321.25M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 23.84M
Shares Floating 16.07M
Shares Outstanding 23.84M
Shares Floating 16.07M
Percent Insiders 0.06
Percent Institutions 102

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.